Biosort secures finance to take individual-based lice control to market

The capital will support final development and market introduction of Biosort’s next-generation lice control technology. 

The system is designed to efficiently remove lice at an early stage, preventing uncontrolled lice population growth, and reducing the need for full-pen interventions.

Geir Stang Hauge, CEO of Biosort, said: “This funding takes us from development into commercial sales. Our focus is simple: continuous lice removal to suppress lice development and greatly reduce needs for well-boat treatments. The goal is improved welfare, lower mortality, better biological control, and ultimately making fish thrive.” 

Founded in 2010, Biosort has developed advanced machine vision, AI, and FishID technology capable of identifying and tracking individual salmon. The system now combines early lice removal with data on individual fish.

Stian Grieg, Investment Manager at Grieg Kapital, said: “We have followed Biosort for several years and are impressed by the team and their technology.

“Sea lice remain one of the greatest challenges in salmon farming, and Biosort’s approach has the potential to improve both lice management and fish health. We are excited to support the company as it moves into commercialisation.”

Carsten Krome, Managing Partner at Hatch Blue, said: “There is a clear shift in the salmon industry toward stronger focus on fish health and greater adoption of new technology.

“Through Blue Revolution Fund, we invest in next-generation aquaculture solutions that improve health and sustainability.

“Together with a strong and experienced investor consortium, we believe Biosort is well positioned to contribute to the next phase of salmon farming.”